CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study

INTRODUCTION AND AIMS: Tamoxifen is an adjuvant drug effective in treating hormone receptor – positive breast cancer. However, 30%–50% of patients relapse and many develop adverse effects, such as hot flashes and fatty liver. Allelic variations altering the activity of cytochrome P450-2D6 enzyme aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wickramage, Ishani, Tennekoon, Kamani Hemamala, Ariyaratne, Merenchi Arachchige Yasantha, Hewage, Asanka Sudeshini, Sundralingam, Tharmini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345689/
https://www.ncbi.nlm.nih.gov/pubmed/28293118
http://dx.doi.org/10.2147/BCTT.S126557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345689/
https://www.ncbi.nlm.nih.gov/pubmed/28293118
http://dx.doi.org/10.2147/BCTT.S126557

Ejemplares similares